Skip to main content
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MIST ISIN · USU6005B1045 LEI · 549300P43IPGW3Q3Y026 US Manufacturing
Filings indexed 346 across all filing types
Latest filing 2026-05-13 Registration Form
Country US United States of America
Listing US MIST

About Milestone Pharmaceuticals Inc.

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company's lead investigational product is etripamil, a novel, fast-acting calcium channel blocker delivered as a nasal spray. This formulation is designed for patient self-administration to terminate episodes of certain heart rhythm disturbances outside of a hospital or emergency department setting. The primary indications under investigation for etripamil are paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), aiming to address unmet needs for acute, at-home treatment of these episodic conditions.

Recent filings

Filing Released Lang Actions
S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Registration Form
2026-05-13 English
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Regulatory Filings
2026-05-13 English
10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Interim / Quarterly Report
2026-05-13 English
SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)
Major Shareholding Notification
2026-03-26 English
3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
Director's Dealing
2026-03-23 English
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Regulatory Filings
2026-03-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.